<SEC-DOCUMENT>0001193125-20-140432.txt : 20200512
<SEC-HEADER>0001193125-20-140432.hdr.sgml : 20200512
<ACCEPTANCE-DATETIME>20200512161539
ACCESSION NUMBER:		0001193125-20-140432
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200512
DATE AS OF CHANGE:		20200512
EFFECTIVENESS DATE:		20200512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neuronetics, Inc.
		CENTRAL INDEX KEY:			0001227636
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38546
		FILM NUMBER:		20869292

	BUSINESS ADDRESS:	
		STREET 1:		3222 PHOENIXVILLE PIKE
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		877-600-7555

	MAIL ADDRESS:	
		STREET 1:		3222 PHOENIXVILLE PIKE
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEURONETICS INC
		DATE OF NAME CHANGE:	20030416
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d932315ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>the Securities Exchange Act of 1934 (Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material under &#167;240.14a-12</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Neuronetics,
Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g932315g0511182915656.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL INFORMATION REGARDING THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON TUESDAY, MAY&nbsp;26,
2020 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;13, 2020, Neuronetics, Inc. (the &#147;Company&#148;) filed a definitive proxy statement with the Securities and Exchange
Commission regarding its Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) to be held on Tuesday, May&nbsp;26, 2020. The following information supplements and relates to that proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2020, the Company issued a press release announcing that the Annual Meeting will be changed from an
<FONT STYLE="white-space:nowrap">in-person</FONT> meeting to a virtual format, conducted solely via live webcast, providing information as to how stockholders can attend and participate in the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE NOTICE SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT. </B></P>
<P STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g932315g0511182915656.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Neuronetics, Inc. Announces Virtual 2020 Annual Meeting of Stockholders </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MALVERN, PA, May</B><B></B><B>&nbsp;12, 2020</B> &#150; Neuronetics, Inc. (Nasdaq: STIM), a commercial stage medical technology company focused on
designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that its 2020 Annual Meeting of Stockholders will be held solely via live webcast due to the public
health impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and out of an abundance of concern for the health and wellbeing of our employees, stockholders and directors. As previously announced, the 2020 Annual Meeting will be
held on May&nbsp;26, 2020 at 9:00 am ET. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attending the Virtual Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To attend and participate in the virtual Annual Meeting of Stockholders, stockholders of record will need to visit
<U>www.virtualshareholdermeeting.com/STIM2020</U> and use their <FONT STYLE="white-space:nowrap">16-digit</FONT> control number (the &#147;Control Number&#148;) received in their notice to log in to this website. Beneficial owners of shares held in
street name will need to follow the instructions provided by the broker, bank or other nominee that holds their shares. We would encourage stockholders to log in to this website and access the webcast before the meeting&#146;s start time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Asking Questions and Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in the proxy
materials for the Annual Meeting, Neuronetics stockholders as of the close of business on April&nbsp;3, 2020 (the record date) are entitled to join the live virtual meeting and shall be able to listen and vote remotely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proxy card included with the proxy materials previously distributed on or about April&nbsp;13, 2020 will not be updated to reflect the change in location
and may continue to be used to vote your shares in connection with the Annual Meeting. The Company encourages eligible stockholders to vote on the proposals prior to the Annual Meeting using the instructions provided in the proxy materials
previously distributed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assistance with the Virtual Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further instructions on how to attend, participate in and vote at the virtual Annual Meeting of Stockholders will be available at
<U>www.virtualshareholdermeeting.com/STIM2020</U>. A support line will also be available on the meeting website on the day of the virtual Annual Meeting should stockholders require assistance with logging in. Digital copies of the company&#146;s
proxy statement and 2019 Annual Report are available at <U>www.proxyvote.com.</U> These materials also are available on the Company&#146;s website at
<U><FONT STYLE="white-space:nowrap">http://ir.neuronetics.com/financial-information/sec-filings</FONT></U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Neuronetics </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life
for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Advanced Therapy System, is a <FONT STYLE="white-space:nowrap">non-invasive</FONT> and <FONT
STYLE="white-space:nowrap">non-systemic</FONT> office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, <FONT STYLE="white-space:nowrap">MRI-strength</FONT> magnetic field that induces electrical currents
designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve
satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan&#146;s national health insurance. Additional information
can be found at <U>www.neuronetics.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements contained herein that relate to the Company&#146;s 2020 Annual Meeting of Stockholders are forward-looking statements within the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Words such as &#147;will be&#148;, &#147;will&#148;, &#147;may&#148; or other similar words or expressions often identify forward-looking statements. Such statements are based on
current expectations only, and are subject to certain risks, uncertainties and assumptions, many of which are beyond our control. Among the factors that could cause the Company&#146;s 2020 Annual Meeting logistical arrangements to change include:
general business and economic conditions; imposition of restrictive governmental regulations implemented to address public health concerns; or operational delays or difficulties because of the novel coronavirus or similar diseases, or uncertainty
regarding the same. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark R. Klausner </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke Partners </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">443-213-0501</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@neuronetics.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chelsey Manko </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vault Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">610-455-2778</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cmanko@vaultcommunications.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g932315g0511182915656.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g932315g0511182915656.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y 0$# 2(  A$! Q$!_\0
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IHNDQ:+I<5E"0VTL[OM"[W8EF.!TR2>*T**')O<=V%%%%(0E%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
